← Back
$RAPP All transactions

Rapport Therapeutics, Inc.

▼ SELL 10b5-1 Plan

$ Value

$65K

Shares

2,200

Price

$30

Filed

Feb 19

Insider

Name

Bredt David

Title

Chief Scientific Officer

CIK

0002022087

Roles

Officer

Transaction Details

Transaction Date

2026-02-17

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

387,075

Footnotes

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | Transaction involved a cash exercise of options to purchase shares of the Issuer's common stock. No shares of the Issuer's common stock were sold as part of this transaction. | 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Filing Info

Accession No.

0001193125-26-059883

Form Type

4

Issuer CIK

0002012593

Bredt David's History

Date Ticker Type Value
2026-02-19 RAPP M $11K
2026-02-19 RAPP M $0
2026-02-17 RAPP $25K
2026-02-17 RAPP $156K
2026-02-17 RAPP $65K
2026-02-02 RAPP A $0
2026-01-15 RAPP $223K
2026-01-15 RAPP $5K
2025-12-31 RAPP A
2025-12-31 RAPP $197K

Other Insiders at RAPP (90d)

Insider Bought Sold Last
Ignelzi Troy A.
Chief Financial Officer
2026-02-02
Ceesay Abraham
Chief Executive Officer
$320K 2026-02-18
Third Rock Ventures V, L.P. $17.2M 2026-04-17
Sevigny Jeffrey
Chief Medical Officer
2026-02-02
Gault Cheryl
Chief Operating Officer
$340K 2026-03-30
Bredt David
Chief Scientific Officer
$182K 2026-02-19
Yeleswaram Krishnaswamy
Chief Development Officer
$1.8M 2026-04-17